Germany launches EUR200 million biotechnology research programme


Berlin – Germany is to invest EUR200 million over the coming 15 years to develop the next generation of biotechnology processes. “The full potential of biotechnology isn’t yet fully exploited”, said BMBF State Secretary Helge Braun during the presentation of the new Biotechnology 2020 Plus programme in Berlin. “We can change this by applying engineering principles to biotechnology.” A long-term goal of the ambitious programme is to separate biological functions from cells, and to create robust reaction modules that can mimic biological processes even under harsh reaction conditions. This would enable engineers to integrate the water-soluble biological processes into existing industrial value chains, for example using cell-free photosynthesis modules for energy production, or artificial enzymes or cell modules to produce chemicals in a solvent-free environment. Because most of these goals are currently more vision than reality, the Ministry for Research has kicked off a so-called strategy process that brings together experts from a variety of fields to discuss the kinds of projects required to realise the biologisation of industrial processes. Four major research organisations have signed a memorandum of understanding to contribute to the process. Synthetic biology is expected to play an important role in the programme.



Martinsried – SuppreMol GmbH has enrolled the first patient in a Phase Ib/IIa clinical trial with SM101, a treatment for Idiopathic Thrombocytopenic Purpura (ITP). Up to 36 patients will receive 4 weekly doses of the recombinant,...



Life Technologies PD-Direct® has partnered with Cytovance Biologics to demon­strate rapid process transfer and scale-up using new media developed for fed batch processes and DASGIP Bioreactors. The new media were developed by...



Tübingen — German mRNA vaccine specialist CureVac GmbH has secured a 27.6 million euro financing round with Dievini Hopp BioTech Holding. The company has announced that it will use the proceeds to drive forward its programmes for...



Berlin - On Monday, German NOXXON Pharma AG announced the successful completion of a Phase I trial with the 1st "Spiegelmer" NOX-A12, an antagonist of stromal cell-derived factor-1 (SDF-1). Final data analysis demonstrated an...



Berlin/Chicago – Despite the financial crisis, the German biotechnology sector grew in the last year. According to a brand-new biotech-report commissioned by the German Research Ministry and published just a couple of days...



Munster – Germany’s federal state North-Rhine Westfalia is to channel EUR 80million into the medical applications of stem cell research. On Friday, the country’s minister Juergen Ruettgers announced that the money will be used...



Wuppertal – Bayer’s anti-infectives spin-out AiCuris has raised EUR 55 million in this year’s largest financing round of a German biotech company lead by the existing shareholders. The money will be used to push Aicuris clinical...



Berlin - On March 30th, Berlin-based biomarker specialist Epigenomics, successfully raised EUR 33,1 million at the public market through the placement of 14,697,361 new shares. The offering started on March 15 at a subscription...

Displaying results 111 to 120 out of 454

< Previous 111-120 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%


  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015

Current issue

All issues